Thomas Pollare
Chairman and member of the board since 2017.
Born: 1953
Education/experience: Thomas Pollare holds an M.D. from Karolinska Institutet and a Ph.D. from Uppsala University. He was previously a partner in the Venture Capital company 3i. He has held VP positions at both Pharmacia Corp and Schering-Plough Inc. He has been responsible for the market approval of several pharmaceutical products in various therapeutic areas and which generated billions in annual sales. Thomas has international experience of board work in both major corporations, start-up companies, public companies and private equity investments.
Current assignments: Chairman of the Board and CEO of Oncolution AB. Chairman of the Boards of AC Intressenter AB, Sinfonia Biotherapeutics AB, AlzeCure Discovery AB and Stiftelsen AlzeCure. Member of the boards of Psilox AB and Premalux AB.
Completed assignments (past five years): Chairman of the boards of A3P Biomedical AB and BioWorks Technologies AB. Member of the boards of Pharmaceuticals Sales & Development Sweden AB, Cereno Scientific AB, Premacure Holding AB, Premacure AB, Xellia Pharmaceuticals ApS and SSI Diagnostica A/S.
Holding: 1,501,293 shares .
Dependent in relation to the company and company management, but independent in relation to the company’s largest shareholders.
Ellen Donnelly
Board member since 2018.
Born: 1974
Education/experience: Ellen Donnelly has a Ph.D. from Yale University Medical School (USA). Ellen has previously held various executive positions in clinical development, project management, research and strategy at Pfzer. Prior to joining Pfzer, Ellen held various positions in American biotechnology and management consultancy companies. Ellen’s experience in Swedish biotech includes CEO of Modus Therapeutics (2016 – 2019) and she is currently CEO of Abliva AB, a biotech company based in Lund focused on mitochondrial disease.
Current assignment: CEO, Abliva AB. Board member of Modus Therapeutics
Completed assignments (past five years): CEO of Modus Therapeutics Holding AB (publ) and Modus Therapeutics AB. CEO, Epigenetics Division of Juvenescence; CEO, Souvien Therapeutics.
Holding: No shareholding.
Independent in relation to the company, company management and the company’s major shareholders
Janet Hoogstraate
Board member since 2023
Born: 1967
Education/experience: Dr Janet Hoogstraate has many years’ experience in life science, with leading roles at Astra Zeneca, among others. She has a PhD in Biopharmaceutical Sciences from the University of Leiden in the Netherlands and an eMBA from Hult International Business School. Janet has a great interest and knowledge in neuroscience research and has been, among other things, chairman of the board of the Stockholm Brain Institute. Janet is today CEO of NorthX Biologics AB, and her extensive experience in preclinical research, the pain area and biotech will be a great asset for AlzeCure.
Current assignment: CEO of NorthX Biologics AB. Member of the board and CEO of Hoogstraate Consulting AB. Member of the board of Mireca Medicines GmbH. Member of the Advisory Board for Dutch Chamber of Commerce in Sweden. Member of the Portfolio Management Board for ENABLE2.
Completed assignments (past five years): Managing Director Valneva Sweden AB.
Holding: 25,000 shares.
Independent in relation to the company, company management and the company’s major shareholders
Eva Lilienberg
Board member since 2021.
Born: 1956
Education/experience: Eva Lilienberg holds an MSc in Pharmaceutical sciences. Eva has a broad regulatory and commercial international experience. She has also a solid experience of drug development from various senior management positions within New Products/Regulatory Affairs area at Merck, Sharp & Dohme (MSD).and have led international teams in purpose to optimize development programs to get pharmaceutical products approved, reimbursed and commercially viable. Eva has worked actively with inter alia FDA and EMA. Eva has also held various positions in AstraZeneca and HMR (now Sanofi). She has acted as Regulatory Affairs consultant in small and mid size companies. Certified Director by the Swedish Academy of Board of Directors.
Current assignments: Consultant and CEO of Kapitel Tre AB. Board member of the Regulatory Affairs section of the Swedish Society of Pharmaceutical Sciences.
Completed assignments (past five years): Service Area lead/Principal Consultant for drug development project at NDA Regulatory Services AB.
Holding: 2,500 shares.
Independent in relation to the company, company management and the company’s major shareholders.
Ragnar Linder
Board member since 2017.
Born: 1953
Education/experience: Ragnar Linder has a Master of Science degree in Chemical Engineering from KTH Royal Institute of Technology. Ragnar is a co-founder of Pygargus, a research company in the field of realworld evidence, which was bought by IMS Health (currently IQVIA) in 2013 and in which Ragnar has held senior positions ever since. He has also held several senior positions in Amgen Nordic (CEO), Aventis, HMR and Hoechst. Ragnar has also been a member of the boards of several biotech, pharmaceutical and CRO companies. Today, Ragnar is an independent consultant.
Current assignments: Member of the board of Pharmacolog i Uppsala AB, Tegnér Biotech Consulting AB and 3D Trace AB.
Completed assignments (last five years): Member of the board of R. Linder Holding AB.
Holding: 49,698 shares.
Independent in relation to the company, company management and the company’s major shareholders.
Holdings in AlzeCure Pharma AB as of September 30, 2023.